Quarterly report · Q3
4564.TEDINET S100SU6F
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥466m | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥700m | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥973m | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | −¥905m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥986m | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥929m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥985m | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥912m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥931m | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.4bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥275m | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥656m | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥599m | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-4.68 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.27 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.3% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥261m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥175m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥634,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥427,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥537m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | −¥712m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥290m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥79m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥536m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | −¥615m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 312
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -289504000 | JPY |
| Operating income | Prior1YTDDuration | -904947000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 427000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 465578000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 466006000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 466006000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 206000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 206000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -206000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 634000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 465578000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 466212000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -206000 | JPY |
| Net sales | CurrentYTDDuration | 466006000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -536927000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -174587000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -711514000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -261237000 | JPY |
| Operating income | CurrentYTDDuration | -972752000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第23期第３四半期（自 2023年10月１日 至 2023年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | OncoTherapy Science, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 嶋田 順一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区東田町１番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044－201－6429 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)管理本部統括取締役 朴 在賢 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区東田町１番地２ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044－201－6429 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)管理本部統括取締役 朴 在賢 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05363 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45640 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Filer name in english | FilingDateInstant | OncoTherapy Science, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |